Eikon

Eikon Research Upgrades to Unanet GovCon ERP and CRM

Retrieved on: 
Wednesday, February 28, 2024

DULLES, Va., Feb. 28, 2024 /PRNewswire/ -- Unanet, the leading provider of project-based enterprise resource planning (ERP) and customer relationship management (CRM) for government contractors (GovCons), today announced that Eikon Research has selected Unanet GovCon ERP and CRM to deliver modern financial, project, and relationship management solutions that will help it expand its business in new areas.

Key Points: 
  • Huntsville radar engineering firm readies for growth by discarding inefficient, off-the-shelf system
    DULLES, Va., Feb. 28, 2024 /PRNewswire/ -- Unanet, the leading provider of project-based enterprise resource planning (ERP) and customer relationship management (CRM ) for government contractors (GovCons), today announced that Eikon Research has selected Unanet GovCon ERP and CRM to deliver modern financial, project, and relationship management solutions that will help it expand its business in new areas.
  • After an initial review of several systems that included expensive and overwhelming legacy software and a smaller system that lacked security, Eikon Research chose Unanet because it was a "one-stop shop" solution for its ERP and CRM needs.
  • "Unanet will build infrastructure that makes sense for our growth by helping us onboard people better and streamline our processes," said Jason Cunningham, chief operating officer at Eikon Research. "
  • Today, more than 2,000 GovCons have selected Unanet ERP GovCon and Unanet CRM because the solutions have the right mix of functionality and accessibility while also offering the ability to scale and grow seamlessly.

Eikon Therapeutics to Provide Corporate Updates at the 42nd Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 8, 2024

“Eikon has made enormous progress in the development of advanced imaging tools that aid the discovery of important new therapeutics.

Key Points: 
  • “Eikon has made enormous progress in the development of advanced imaging tools that aid the discovery of important new therapeutics.
  • This program is led by Eikon with its collaboration partner, Impact Therapeutics, which is responsible for trial oversight in greater China.
  • Eikon Systems Business Unit Established: Eikon has developed a suite of instruments that permits detailed, automated characterization of protein motion in living cells.
  • An archived recording of Eikon’s presentation at the J.P. Morgan Healthcare Conference can be accessed at: www.EikonTx.com/#news .

Pliops Elevates Performance, Reliability for High-Performance Computing Applications

Retrieved on: 
Tuesday, November 14, 2023

SAN JOSE, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- In conjunction with this week’s SC23, which focuses on high-performance computing, networking and storage, Pliops, a leading provider of data processors for cloud and enterprise data centers, is highlighting its storage solutions addressing the demands of these massively complex, data-laden applications.

Key Points: 
  • Running on the Pliops Extreme Data Processor (XDP) , the Pliops portfolio of XDP Data Services maximize data center infrastructure investments by exponentially increasing application performance, storage reliability and capacity, as well as overall stack efficiency.
  • At SC23, Pliops will discuss how XDP Data Services help optimize data infrastructure and accelerate modern workloads, while in tandem reducing TCO by 50%.
  • For example, drug discovery and development company Eikon Therapeutics is using Pliops XDP to improve overall operations and address data growth, with a particular focus on performance, reliability, high availability and disaster recovery.
  • The Pliops solution impressed the Eikon storage team and has significantly improved performance, as well as reduced operational overhead.

Eikon Therapeutics Announces the Election of Robert L. Huffines to its Board of Directors

Retrieved on: 
Monday, December 4, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231204280302/en/
    Eikon Therapeutics announces the election of Robbie Huffines to its Board of Directors.
  • Mr. Huffines is also a member of the board of Nextech Invest Ltd., a cancer-focused venture capital firm headquartered in Zurich, Switzerland.
  • “As recently announced, I am retiring in early 2024 from J.P Morgan and am honored to be joining the Eikon Therapeutics Board.
  • “I find Eikon’s breakthrough enabling technology and world class research talent to be a powerful match with enormous potential.”

Quantum Myriad™ All-Flash File and Object Solution Now Generally Available

Retrieved on: 
Wednesday, November 29, 2023

SAN JOSE, Calif., Nov. 29, 2023 /PRNewswire/ -- Quantum Corporation (NASDAQ: QMCO), the leader in solutions for video and unstructured data, announces that Quantum Myriad™, an all-flash, scale-out file and object storage software platform for the enterprise, is now generally available for purchase. First released to early-access customers in April of this year, Myriad has demonstrated in testing that it delivers deployment flexibility and consistent high performance for data intensive workloads. This is in large part due to its modern cloud-native architecture that makes it an easy-to-use solution that overcomes the limitations of hardware-centric designs and enables customers to adapt to future storage needs while reducing the burden on over-extended IT staff.

Key Points: 
  • In early-access testing, cloud-native solution demonstrates high performance, ease of use
    SAN JOSE, Calif., Nov. 29, 2023 /PRNewswire/ -- Quantum Corporation (NASDAQ: QMCO), the leader in solutions for video and unstructured data, announces that Quantum Myriad™, an all-flash, scale-out file and object storage software platform for the enterprise, is now generally available for purchase.
  • For these compute-intensive needs, they require an all-flash solution that has low latency and consistent high performance.
  • As we pursue this goal we constantly evaluate and advise our peer companies and researchers on architecture design and performance.
  • The new solution has already received multiple industry accolades including the CRN Best Tech Innovators and NAB New Product of the Year awards.

Eikon Therapeutics Announces Business Update, Highlighting Pipeline and Clinical Development Progress

Retrieved on: 
Monday, September 11, 2023

“Powered by the contributions of our cross-disciplinary organization, Eikon has made important progress in both our early- and clinical-stage pipeline programs,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics.

Key Points: 
  • “Powered by the contributions of our cross-disciplinary organization, Eikon has made important progress in both our early- and clinical-stage pipeline programs,” said Roger M. Perlmutter, M.D., Ph.D., CEO and Board Chair of Eikon Therapeutics.
  • “Our advanced analytical tools have enabled Eikon to capitalize on near-term opportunities to bring new medicines to patients.
  • Eikon believes that adverse experiences associated with BDB001 treatment are manageable using Eikon’s proposed clinical dosing regimen.
  • Eikon anticipates initiating Phase 1 clinical studies of IMP1734 in the United States and other jurisdictions in the fourth quarter.

Morphisec Protects Hedge Fund Endpoints and Financial Trading Platforms from Ransomware and Advanced Attacks

Retrieved on: 
Wednesday, August 30, 2023

BOSTON and BEER-SHEVA, Israel, Aug. 30, 2023 /PRNewswire-PRWeb/ -- Morphisec, the world's leading provider of prevention-first endpoint security software, today released a case study detailing the implementation of Automated Moving Target Defense (AMTD) alongside endpoint protection platforms (EPP) in financial services for advanced in-memory and evasive attack protection.

Key Points: 
  • "1
    Alternative investment firms and hedge funds increasingly face a range of threats that directly target firm infrastructure including malware, ransomware, account compromise or takeover and phishing.
  • Additionally, firms rely on third-party financial and trading platforms to conduct activities.
  • Financial platforms are often accessed through dedicated private line infrastructure that effectively bypasses firewall and other perimeter security solutions, thereby increasing risk.
  • Morphisec protects more than nine million endpoints across more than 5,000 global customers including financial institutions, banks, alternative investment funds and hedge funds.

dxFeed Integrates Indices into Refinitiv, Enabling Wider Access and Enhanced Financial Insights

Retrieved on: 
Wednesday, August 9, 2023

This integration marks a significant milestone in dxFeed's journey to improve accessibility and insights for financial professionals and investors worldwide.

Key Points: 
  • This integration marks a significant milestone in dxFeed's journey to improve accessibility and insights for financial professionals and investors worldwide.
  • As part of this collaboration, dxFeed's indices will be seamlessly visible across Refinitiv 's suite of financial services, including their widely-used Eikon platform.
  • RICs facilitate efficient data retrieval and enable users to easily access dxFeed's indices through Refinitiv's platforms and services.
  • Custom Indices Upload: In addition to dxFeed's proprietary indices, users will have access to the indices created for dxFeed's customers and partners.

Cleave Therapeutics Announces Acquisition of Clinical and Preclinical Assets

Retrieved on: 
Thursday, July 20, 2023

Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that CASI Pharmaceuticals (NASDAQ: CASI) has acquired the global rights to the company’s clinical asset, CB-5339, and Eikon Therapeutics has acquired rights to the company’s pre-clinical assets.

Key Points: 
  • Cleave Therapeutics, Inc., a clinical-stage biopharmaceutical company, today announced that CASI Pharmaceuticals (NASDAQ: CASI) has acquired the global rights to the company’s clinical asset, CB-5339, and Eikon Therapeutics has acquired rights to the company’s pre-clinical assets.
  • Eikon Therapeutics is a clinical-stage company working to advance breakthrough therapeutics through the purposeful integration of engineering and science.
  • “Both CASI and Eikon have unique capabilities and the expertise to continue advancing Cleave programs for patients with unmet needs in cancer and other indications,” said Amy Burroughs, president and chief executive officer of Cleave Therapeutics.
  • “The robust scientific and clinical insights the Cleave team has generated over the past decade will inform future development across multiple novel targets and disease areas.

Experience the Power of the Eikons in FINAL FANTASY XVI, Now Available

Retrieved on: 
Thursday, June 22, 2023

Today, SQUARE ENIX® announced that the release of FINAL FANTASY®XVI , the latest standalone entry in the critically-acclaimed FINAL FANTASY franchise, is now available for PlayStation®5 (PS5®) consoles.

Key Points: 
  • Today, SQUARE ENIX® announced that the release of FINAL FANTASY®XVI , the latest standalone entry in the critically-acclaimed FINAL FANTASY franchise, is now available for PlayStation®5 (PS5®) consoles.
  • FINAL FANTASY XVI is the first true action role-playing game (RPG) in the beloved series, combining a dynamic real-time action combat system and RPG features to provide an expansive and thrilling gameplay experience.
  • The FINAL FANTASY XVI Demo is the perfect opportunity for players to jump into the realms of Valisthea to experience the beginnings of protagonist Clive Rosfield’s epic tale.
  • FINAL FANTASY XVI is rated M (Mature) and is now available for the PlayStation®5 console.